<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04990297</url>
  </required_header>
  <id_info>
    <org_study_id>RAISE</org_study_id>
    <nct_id>NCT04990297</nct_id>
  </id_info>
  <brief_title>Risk Stratification of Multicenter Patients With Heart Failure</brief_title>
  <official_title>Risk Stratification of Multicenter Patients With Heart Failure: Clinic, Labortary Test and Cardiovascular Magnetic Resonance Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences, Fuwai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences, Fuwai Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is the final stage of the heart disease. The prevalence of heart failure&#xD;
      continues to rise, but the diagnosis and treatment is not satisfactory. At present, there is&#xD;
      no relatively ideal model to predict the adverse cardiovascular events in patients with heart&#xD;
      failure and carry out effective clinical intervention. Cardiac magnetic resonance can&#xD;
      directly reflect the cardiac structure, function and myocardial characteristics of patients&#xD;
      with heart failure. This study aimed to establish the relationship between cells, molecules&#xD;
      and clinic with the help of image bridge, and establish the risk model of heart failure based&#xD;
      on demographic data, symptoms, laboratory tests and emerging magnetic resonance imaging&#xD;
      technologies (T1 mapping / ECV, feature tracking, CEST).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is the final stage of the heart disease which refers to the disorder of&#xD;
      systolic and (or) diastolic function of the heart. At present, there are about 50 models to&#xD;
      predict the risk of death in patients with heart failure. Most models use demographic,&#xD;
      complications, and laboratory tests to risk HF patients. The main risk factors included age,&#xD;
      renal function, blood pressure, sodium level, ejection fraction, gender, BNP level, NYHA&#xD;
      cardiac function classification, diabetes mellitus and body mass index. However, there is no&#xD;
      relatively ideal model to predict the adverse cardiovascular events in patients with heart&#xD;
      failure and carry out effective clinical intervention. One of the main factors is that the&#xD;
      risk factors of almost all existing heart failure models are mostly based on demographic&#xD;
      data, symptoms, laboratory tests, etc. These indicators are not specific, insensitive and do&#xD;
      not directly reflect the heart status of patients with heart failure. There is a lack of&#xD;
      relevant parameters to reflect the mechanism and its secondary pathophysiological changes of&#xD;
      heart failure.&#xD;
&#xD;
      Cardiovascular magnetic resonance has become an increasingly important noninvasive imaging&#xD;
      tool for the diagnosis, treatment and prognosis of cardiovascular diseases, Emerging&#xD;
      techniques such as T1 / 2 mapping, extracellular volume, perfusion imaging, , BOLD fMRI and&#xD;
      chemical exchange saturation transfer (CEST) imaging have emerged rapidly. It is possible to&#xD;
      interpret the pathogenesis and related pathophysiological changes of heart failure and&#xD;
      establish a new risk model of death and adverse cardiovascular events.&#xD;
&#xD;
      Based on the emerging magnetic resonance imaging technologies (T1 mapping / ECV, feature&#xD;
      tracking, CEST and other technologies), this study aims to establish the relationship between&#xD;
      cells, molecular and clinic with the help of imaging. Through one-stop scanning, we can not&#xD;
      only obtain the relevant information of diagnosis, but also establish the risk model of death&#xD;
      of heart failure based on cardiac magnetic resonance. Through the one-stop magnetic resonance&#xD;
      examination, establishing a comprehensive risk model of cardiac death of heart failure, and&#xD;
      take targeted intervention measures for people with different risks, so as to achieve early&#xD;
      intervention, early treatment, improve the prognosis of patients, and provide guidance for&#xD;
      clinicians.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 28, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause Mortality</measure>
    <time_frame>1-10years</time_frame>
    <description>the incidence of all-cause death the incidence of all-cause death the incidence of all-cause death the incidence of all-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular Death</measure>
    <time_frame>1-10years</time_frame>
    <description>the incidence of cadridovascular death</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Transplantation Heart Transplantation</measure>
    <time_frame>1-10years</time_frame>
    <description>the incidence of Heart Transplantation Heart Transplantation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implantable cardioverter-defibrillator Implantation</measure>
    <time_frame>1-10years</time_frame>
    <description>the incidence of Implantable cardioverter-defibrillator Implantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Due to Heart FailureHeart Transplantation</measure>
    <time_frame>1-10years</time_frame>
    <description>the incidence of Heart Transplantation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Heart Failure</condition>
  <condition>Multicenter Study</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      data of radiology imaging, clinical study and laboratory study&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study is a prospective, multicenter study with HF patients, diagnosed based on the&#xD;
        World Health Organization/International Society and Federation of Cardiology definition of&#xD;
        Heart failure.The inclusion criteria include left ventricular ejection fraction (LVEF)&lt;50%.&#xD;
        LV end-diastolic volume &gt;2SD from normal according to normograms corrected by body surface&#xD;
        area (BSA) and age. We exclude patients with severe arrhythmia; Contraindications to CMR;&#xD;
        Refuse to participate in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. reduced left ventricular ejection fraction (LVEF&lt;50%)&#xD;
&#xD;
          2. LV end-diastolic volume &gt;2SD from normal according to normograms corrected by body&#xD;
             surface area (BSA) and age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1)Severe arrhythmia; 2)Contraindications to CMR 3)Refuse to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Minjie Lu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Fuwai Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Minjie Lu, PhD</last_name>
    <phone>+86-10-88396941</phone>
    <email>coolkan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minjie Lu, PhD</last_name>
      <phone>+86 10 88398175</phone>
      <email>coolkan@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Shah KS, Xu H, Matsouaka RA, Bhatt DL, Heidenreich PA, Hernandez AF, Devore AD, Yancy CW, Fonarow GC. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017 Nov 14;70(20):2476-2486. doi: 10.1016/j.jacc.2017.08.074. Epub 2017 Nov 12.</citation>
    <PMID>29141781</PMID>
  </results_reference>
  <results_reference>
    <citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonz√°lez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20.</citation>
    <PMID>27207191</PMID>
  </results_reference>
  <results_reference>
    <citation>Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R, McAnulty JH, Gunson K, Jui J, Chugh SS. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol. 2006 Mar 21;47(6):1161-6. Epub 2006 Feb 23.</citation>
    <PMID>16545646</PMID>
  </results_reference>
  <results_reference>
    <citation>Rahimi K, Bennett D, Conrad N, Williams TM, Basu J, Dwight J, Woodward M, Patel A, McMurray J, MacMahon S. Risk prediction in patients with heart failure: a systematic review and analysis. JACC Heart Fail. 2014 Oct;2(5):440-6. doi: 10.1016/j.jchf.2014.04.008. Epub 2014 Sep 3. Review.</citation>
    <PMID>25194291</PMID>
  </results_reference>
  <results_reference>
    <citation>Fukushima A, Milner K, Gupta A, Lopaschuk GD. Myocardial Energy Substrate Metabolism in Heart Failure : from Pathways to Therapeutic Targets. Curr Pharm Des. 2015;21(25):3654-64. Review.</citation>
    <PMID>26166604</PMID>
  </results_reference>
  <results_reference>
    <citation>Marwick TH, Shah SJ, Thomas JD. Myocardial Strain in the Assessment of Patients With Heart Failure: A Review. JAMA Cardiol. 2019 Mar 1;4(3):287-294. doi: 10.1001/jamacardio.2019.0052. Review.</citation>
    <PMID>30810702</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U, Kindermann I, Gutberlet M, Cooper LT, Liu P, Friedrich MG. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations. J Am Coll Cardiol. 2018 Dec 18;72(24):3158-3176. doi: 10.1016/j.jacc.2018.09.072. Review.</citation>
    <PMID>30545455</PMID>
  </results_reference>
  <results_reference>
    <citation>G√∂rmeli CA, √ñzdemir ZM, Kahraman AS, Yaƒümur J, √ñzdemir R, √áolak C. The evaluation of non-ischemic dilated cardiomyopathy with T1 mapping and ECV methods using 3T cardiac MRI. Radiol Med. 2017 Feb;122(2):106-112. doi: 10.1007/s11547-016-0701-y. Epub 2016 Oct 27.</citation>
    <PMID>27785679</PMID>
  </results_reference>
  <results_reference>
    <citation>Barison A, Del Torto A, Chiappino S, Aquaro GD, Todiere G, Vergaro G, Passino C, Lombardi M, Emdin M, Masci PG. Prognostic significance of myocardial extracellular volume fraction in nonischaemic dilated cardiomyopathy. J Cardiovasc Med (Hagerstown). 2015 Oct;16(10):681-7. doi: 10.2459/JCM.0000000000000275.</citation>
    <PMID>26090916</PMID>
  </results_reference>
  <results_reference>
    <citation>Inui K, Asai K, Tachi M, Yoshinaga A, Izumi Y, Kubota Y, Murai K, Tsukada YT, Amano Y, Kumita S, Shimizu W. Extracellular volume fraction assessed using cardiovascular magnetic resonance can predict improvement in left ventricular ejection fraction in patients with dilated cardiomyopathy. Heart Vessels. 2018 Oct;33(10):1195-1203. doi: 10.1007/s00380-018-1154-0. Epub 2018 Mar 20.</citation>
    <PMID>29560528</PMID>
  </results_reference>
  <results_reference>
    <citation>Vita T, Gr√§ni C, Abbasi SA, Neilan TG, Rowin E, Kaneko K, Coelho-Filho O, Watanabe E, Mongeon FP, Farhad H, Rassi CH, Choi YL, Cheng K, Givertz MM, Blankstein R, Steigner M, Aghayev A, Jerosch-Herold M, Kwong RY. Comparing CMR Mapping Methods and Myocardial Patterns Toward Heart Failure Outcomes in Nonischemic Dilated Cardiomyopathy. JACC Cardiovasc Imaging. 2019 Aug;12(8 Pt 2):1659-1669. doi: 10.1016/j.jcmg.2018.08.021. Epub 2018 Nov 15.</citation>
    <PMID>30448130</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences, Fuwai Hospital</investigator_affiliation>
    <investigator_full_name>Minjie Lu</investigator_full_name>
    <investigator_title>Vice Director of Magnetic Resonance Imaging</investigator_title>
  </responsible_party>
  <keyword>heart failure</keyword>
  <keyword>cardiovascular magnetic resonance imaging</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Our study data is applicable to other researchers with permmsion.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

